Carlos Vargas,1 Jorge Otero,1 Pilar Archila,6. Claudio Martin,7 Luis Corrales,8 Mauricio Cuello,9. Carlos Ortiz,1 Sandra Franco,1 Rafael Rosell10. 1Medical ...
January 2017
(6 exon 14 skipped and 8 amplified): 13 patients were male (93%), with a median age of 65.7 years (range: 4091), nine current smokers (64%) (40 pack-years, range: 20-60), and eight diagnosed in an advanced stage disease (III and IV) (57%). Correlation with c-MET protein expression by IHC is ongoing, and data will be presented at the meeting. Conclusion: As no concurrent MET mutated and amplified cases were found, our data support prospective identification of both, MET exon 14 skipping mutations and gene amplifications. These mutations define a new subset of NSCLC patients that should be analyzed independently of the status of MET gene copy number. Keywords: MET amplification, FISH, MET exon 14 skipping, MET alterations
P1.02-049 EGFR, KRAS and ALK Gene Alterations in Lung Cancer Patients in Croatia Topic: Driver Genes in NSCLC, Resistance, and Other Marko Jakopovic,1 Luka Brcic,2 Marija Misic,3 Gordana Bubanovic,1 Fran Seiwerth,4 Gordana Drpa,4 Branka Cucevic,4 Mihovil Roglic,4 Sanja Plestina,4 Suazana Kukulj,4 Silvana Smojver-Jezek,4 Sven Seiwerth,3 Miroslav Samarzija1 1Department for Respiratory Diseases “Jordanovac”, University Hospital Centre Zagreb, Zagreb/Croatia, 2Department of Pathology, University of Graz, Graz/Austria, 3Zagreb Medical School, Zagreb/ Croatia, 4University Hospital Centre Zagreb, Zagreb/ Croatia Background: Rates in targetable gene changes varies between different populations of lung cancer patients. Targetable gene changes include changes in EGFR and ALK gene, as well as KRAS gene. Primary aim of this study was to determine mutation status in purely Caucasian Croatian population. Methods: Rates in targetable gene changes varies between different populations of lung cancer patients. Targetable gene changes include changes in EGFR and ALK gene, as well as KRAS gene. Primary aim of this study was to determine mutation status in purely Caucasian Croatian population. Results: During 6 months period 324 newly diagnosed primary lung adenocarcinoma were tested. Out of 324 tested patients, 194 were males (60%) and 130 females (40%) mean age 64 years (range 35 to 88 years). Vast majority of patients were in stages 3 and 4 (more than
Abstracts
S517
80%). Among males, 87% of patients were ever smokers, and among females 61% of patients were ever smokers. Significantly higher rates of ever smokers were recorded among males. EGFR mutations were present in 15.7% of patients (51 patients). There was a difference in EGFR mutation rates between males and females (5.6 vs 30.8%, p
